7.125
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Fennec Pharmaceuticals Inc Borsa (FENC) Ultime notizie
FENC (Fennec Pharmaceuticals) posts far wider than expected Q4 2025 loss even as shares tick higher. - Newser
Book value per share of Fennec Pharmaceuticals Inc. – TSX:FRX - TradingView
Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,781 Shares of Stock - MarketBeat
Director at Fennec (NASDAQ: FENC) sells shares after tax-related option exercise - Stock Titan
FENC (NASDAQ: FENC) insider files Form 144 to sell 10,781 shares - Stock Titan
Fennec (NASDAQ: FENC) CCO acquires 168 newly released shares - Stock Titan
Fennec Pharmaceuticals (NASDAQ: FENC) CSO gains 155 vested shares - Stock Titan
Fennec (FENC) CEO acquires 1,159 shares as restrictions lift - Stock Titan
Fennec Pharmaceuticals (FENC) CFO gains 1,703 additional shares - Stock Titan
Restricted share vesting adds 168 shares for Fennec (FENC) CMO - Stock Titan
FENC Stock Price, Quote & Chart | FENNEC PHARMACEUTICALS INC (NASDAQ:FENC) - ChartMill
Director to retire as Fennec Pharmaceuticals (FENC) Board shrinks to five seats - Stock Titan
1.98M shares disclosed by Fennec holders (NASDAQ: FENC) in Schedule 13G - Stock Titan
Large equity incentive proposals at Fennec Pharmaceuticals (NASDAQ: FENC) 2026 meeting - Stock Titan
(FENC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
FENC Fennec Pharmaceuticals Inc. reports wider than expected Q4 2025 loss, as shares rise nearly 8 percent in today’s trading.FCF Yield - Cổng thông tin điện tử Tỉnh Sơn La
Fennec Showcases New PEDMARK Data at 2026 ASCO - TipRanks
Fennec Pharmaceuticals (FENC) to feature four PEDMARK ototoxicity studies at ASCO 2026 - Stock Titan
Fennec Pharmaceuticals advances PEDMARK as four abstracts accepted for ASCO scientific program - Traders Union
Fennec Pharmaceuticals : Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - marketscreener.com
Fennec Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - marketscreener.com
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - The Manila Times
Four ASCO studies spotlight hearing-loss risk tied to cisplatin - Stock Titan
Fennec Pharmaceuticals (FENC) Stock One Cancels Other (Weakens) 2026-04-20Most Watched Stocks - Xã Vĩnh Công
(FRX) Strategic Equity Report (FRX:CA) - Stock Traders Daily
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Fennec Pharmaceuticals (FENC) Receives a Buy from Wedbush - The Globe and Mail
Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush - MarketBeat
(FENC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fennec Pharmaceuticals (FENC) Stock Dividend Capture (Ticks Up) 2026-04-15Senior Analyst Forecasts - Cổng thông tin điện tử tỉnh Lào Cai
(FRX) Trading Report (FRX:CA) - Stock Traders Daily
Treasury Yields: Can Fennec Pharmaceuticals Inc stock outperform in a bear market2026 Reactions & Verified Entry Point Detection - baoquankhu1.vn
US Market Recap: What is the long term forecast for Fennec Pharmaceuticals Inc stock2026 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Stock Recap: Can Fennec Pharmaceuticals Inc expand its profit marginsGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving AverageWhat's Next? - MarketBeat
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Aug Spikes: Why is Fennec Pharmaceuticals Inc stock going down2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study - Investing.com India
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals Announces New Investigator-Sponsored Study of PEDMARK® for Preventing Cisplatin-Induced Hearing Loss in AYA and Adult Cancer Patients - Minichart
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan
Fennec Pharmaceuticals Inc. Announces Investigator-Sponsored Study of PEDMARK in AYA and Adult Patients With Solid Tumors Receiving Cisplatin - marketscreener.com
Fennec Pharmaceuticals urges focus on community and science to shape a healthier world - Traders Union
Fennec Pharmaceuticals: University Of Arizona Cancer Center Investigator-Sponsored Study Advances PEDMARK In AYA And Adult Cancer Patients - Pulse 2.0
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - Bitget
Can a hearing-loss drug help more adults on cisplatin? Arizona study starts - Stock Titan
Trend Recap: Can Fennec Pharmaceuticals Inc sustain earnings growth2026 Short Interest & Step-by-Step Swing Trade Plans - baoquankhu1.vn
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
FENC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):